From: A systematic review of biomarkers for disease progression in Parkinson’s disease
Biomarker modality | Number of studies investigating biomarker modality | Number of studies reporting a significant association between biomarker modality and a clinical measure of disease progression |
---|---|---|
FDOPA brain PET | 5 | 0 |
DAT brain PET or SPECT | 8 | 3 |
FDG brain PET | 2 | 2 |
SPECT to investigate cerebral blood flow | 3 | 2 |
MRI brain | 1 | 0 |
Electrophysiological tests | 1 | 0 |
Other | 1 | 0 |